STOCK OPTIONS (Details Narrative) - USD ($) |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2025 |
Mar. 31, 2024 |
Feb. 09, 2023 |
|
Class of Warrant or Right [Line Items] | |||
Options, grants in period | $ 0 | $ 731,548 | |
Options, vested in period | 82,057 | 0 | |
Compensation expense | $ 82,057 | 92,719 | |
Aggregate intrinsic value, exercisable | 32,220,803 | ||
Estimated fair value of common stock | $ 0.001 | ||
Warrant [Member] | |||
Class of Warrant or Right [Line Items] | |||
Compensation expense | $ 389,179 | $ 390,747 | |
Future compensation cost | $ 312,565 | ||
Aggregate intrinsic value, exercisable | 0 | ||
Estimated fair value of common stock | $ 0.05 |
X | ||||||||||
- Definition Class of warrant of right exercisable warrants. No definition available.
|
X | ||||||||||
- Definition Share based compensation arrangement by share based payment award options granted in period fair value 1. No definition available.
|
X | ||||||||||
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of cost not yet recognized for nonvested award under share-based payment arrangement. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Details
|